PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Celeros, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Celeros Equipment Selected by Sanofi Pasteur for New Vaccine Production Facility - Celeros, Inc., announced that it was selected by Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, as a supplier of advanced centrifuge separations equipment for a new vaccine facility in Marcy l’Etoile, France
Celeros Equipment Selected by Sanofi Pasteur for New Vaccine Production Facility

 

NewswireToday - /newswire/ - Foxboro, MA, United States, 2011/01/04 - Celeros, Inc., announced that it was selected by Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, as a supplier of advanced centrifuge separations equipment for a new vaccine facility in Marcy l’Etoile, France.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Celeros was selected based on their breakthrough technologies and expertise in solid-liquid separations. The equipment is recognized as a new generation centrifuge system of industrial interest. Through a tight collaboration with Sanofi Pasteur this new equipment should be implemented in one of Sanofi Pasteur cutting-edge vaccine production facilities in Marcy l’Etoile.

The new automated centrifuges from Celeros, once qualified, will enable Sanofi Pasteur to achieve a closed system process approach and a high level of automation with improved productivity.

"Our respective organizations have a similar focus on process improvements to drive quality and productivity," said Greg Cybulski, Director of Sales and Marketing for Celeros. "As with all our partners, we are pleased to be working closely with Sanofi Pasteur to help them achieve their goals."

Among the new equipment purchased by Sanofi Pasteur are the latest version, midsized, Celeros Automated Piston Discharge (APD), high performance centrifuges, capable of precise, low moisture solids recovery, superior to disk machines.

About Sanofi Pasteur

Sanofi Pasteur (sanofipasteur.com, sanofipasteur.us), the vaccines division of Sanofi-Aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development.

About Celeros, Inc.

Celeros, Inc. (celerosinc.com) creates business advantages for biotech and pharmaceutical organizations by delivering practical and sustainable innovation to enable significant advancements in process yield and cost control. Pioneering patented Automated Discharge technology for demanding Biotech and pharmaceutical separation applications, Celeros’ innovations provide an enduring platform for customer success. Celeros is driving process improvement and operational excellence for customers worldwide.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Celeros, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Celeros Equipment Selected by Sanofi Pasteur for New Vaccine Production Facility

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Greg Cybulski - Celerosinc.com 
508-698-3080 greg.cybulski[.]celerosinc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Celeros, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Celeros, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution
PleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions
First Pulmonary Embolism Patients in Hong Kong Treated with the EKOS® System
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)